This company is no longer active
ContraFect (22R) Stock Overview
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
22R Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
ContraFect Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.56 |
| 52 Week High | US$270.48 |
| 52 Week Low | US$4.00 |
| Beta | 0.43 |
| 1 Month Change | 0% |
| 3 Month Change | -5.00% |
| 1 Year Change | -97.97% |
| 3 Year Change | -98.86% |
| 5 Year Change | -99.63% |
| Change since IPO | -99.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 22R | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | -0.5% |
| 1Y | -98.0% | -7.7% | 4.6% |
Return vs Industry: 22R underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 22R underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 22R volatility | |
|---|---|
| 22R Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 22R's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 22R's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 23 | Roger Pomerantz | www.contrafect.com |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections.
ContraFect Corporation Fundamentals Summary
| 22R fundamental statistics | |
|---|---|
| Market cap | €2.16m |
| Earnings (TTM) | -€60.03m |
| Revenue (TTM) | n/a |
Is 22R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 22R income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$65.15m |
| Earnings | -US$65.15m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -41.61 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 22R perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/14 13:01 |
| End of Day Share Price | 2023/02/14 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ContraFect Corporation is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Brean Capital Historical (Janney Montgomery) |
| Louise Chen | Cantor Fitzgerald & Co. |
| Keay Nakae | Chardan Capital Markets, LLC |